Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if eltrombopag can help to increase the
number of platelets in patients with CLL. The safety of this drug will also be studied.